Please try another search
For the three months ended 31 March 2022, Jin Yang Pharmaceutical Co., Ltd. revenues increased 33% to W17.65B. Net income increased 94% to W1.72B. Revenues reflect Other finished goods segment increase from W805.6M to W2B, Other revenues segment increase of 40% to W3.15B. Net income benefited from Expense of Allow. for DA increase from W125.8M to W394.5M (income), Employee Benefits decrease of 11% to W703.7M (expense).
Period Ending: | Mar 31, 2024 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Revenue | 27298.32 | 24068.44 | 23047.78 | 22360.49 |
Gross Profit | 17456.4 | 15561.99 | 14197.16 | 13438.78 |
Operating Income | 2205.89 | 3276.97 | 3334.79 | 3483.18 |
Net Income | 1866.73 | 3916.88 | 4997.24 | 2760.24 |
Period Ending: | Mar 31, 2024 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Assets | 124281.03 | 123682.16 | 121411.18 | 118113.2 |
Total Liabilities | 34450.03 | 37151.69 | 38793.05 | 39390.37 |
Total Equity | 89831 | 86530.47 | 82618.14 | 78722.83 |
Period Ending: | Mar 31, 2024 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | 3334.5 | 3970.7 | 1178.45 | 2631.6 |
Cash From Investing Activities | -3442.56 | -2693.92 | -253.19 | -70.09 |
Cash From Financing Activities | -333.76 | -66.42 | -1572.03 | -264.25 |
Net Change in Cash | -441.82 | 1210.36 | -646.76 | 2297.26 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review